{"filing":{"accession_number":"0001599298-26-000043","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"smmt-20260530.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000043/smmt-20260530.htm"},"events":[{"id":7938,"run_id":6969,"accession_number":"0001599298-26-000043","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Summit Therapeutics disclosed results from two clinical trials (AK112-206 Phase II and HARMONi-6 Phase III) for ivonescimab in colorectal cancer via press releases and a scheduled investor conference call. While this represents material clinical trial data that would affect investor assessment of the company's pipeline, it does not fit the specific \"earnings_release\" category (which typically refers to financial results) nor any other more specific event type. This is a material clinical development disclosure appropriately classified as other_material.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3327,"accession_number":"0001599298-26-000043","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Summit Therapeutics disclosed results from two clinical trials (AK112-206 Phase II and HARMONi-6 Phase III) for ivonescimab in colorectal cancer via press releases and a scheduled investor conference call. While this represents material clinical trial data that would affect investor assessment of the company's pipeline, it does not fit the specific \"earnings_release\" category (which typically refers to financial results) nor any other more specific event type. This is a material clinical development disclosure appropriately classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:07:11.418382+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3327,"accession_number":"0001599298-26-000043","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Summit Therapeutics disclosed results from two clinical trials (AK112-206 Phase II and HARMONi-6 Phase III) for ivonescimab in colorectal cancer via press releases and a scheduled investor conference call. While this represents material clinical trial data that would affect investor assessment of the company's pipeline, it does not fit the specific \"earnings_release\" category (which typically refers to financial results) nor any other more specific event type. This is a material clinical development disclosure appropriately classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:07:11.418382+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-06-01"}]}